[Combined therapy with microwave hyperthermia and adriamycin in MM2-bearing mice].
C3H/He mice were inoculated i.p. with synergic MM2 tumor cells(2 X 10(6) cells/mouse), and subsequently treated either by systemic hyperthermia induced by microwave irradiation (2450 MHz)alone, administration of ADM alone, or a combination of both. The mice were exposed to hyperthermia for 5 minutes everyday at an output of 10, 20 or 30 watts. ADM was administered i.p. for 3 days at dose levels of 0.025 mg/kg, 0.05 mg/kg or 0.075 mg/kg body weight. The mean survival time and the mean relative body weight were recorded. From these data, tumor-suppressing effects of the treatments were analysed by one-way or two-way variance analysis. Mice treated with 30-watt microwave irradiation survived significantly longer than control mice without treatment (P less than 0.05), as did mice treated with ADM alone (P less than 0.01). The mean relative body weight was similar among the microwave, ADM and control groups. When the mice were given microwave treatment combined with ADM, significant difference was observed in the mean survival time by one-way variance analysis (P less than 0.01), but no significant difference was observed by two-way variance analysis. The best condition of mice and the optimal dose of ADM still remain to be determined to facilitate more efficient tumor-suppression using this combination therapy.
D000818:Animals; D001835:Body Weight; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D006979:Hyperthermia, Induced / Q000379:methods; D008114:Liver Neoplasms, Experimental / Q000628:therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D008872:Microwaves / Q000627:therapeutic use*; D014916:Whole-Body Irradiation
D004317:Doxorubicin